Leveraging University of Glasgow and University of Southern Denmark research, Caldan is targeting a free fatty acid receptor associated with fatty liver disease and type 2 diabetes.

Caldan Therapeutics, a UK-based metabolic disease therapy developer exploiting research from University of Glasgow and University of Southern Denmark, secured £2m ($2.4m) on Tuesday in a round led by research charity LifeArc. LifeArc invested $1.8m to lead the round, which was also backed by venture capital firm Epidarex Capital. Founded in 2015, Caldan is developing…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.